Clinical Trial Update: A Study of Carboplatin and DOXIL Plus Bevacizumab in Patients With Platinum Sensitive Recurrent Ovarian, Fallopian Tube and Primary Peritoneal Cancers [Phase 2]

View source ↗

Summary

Phase 2 study of carboplatin with DOXIL (liposomal doxorubicin) plus bevacizumab in platinum-sensitive recurrent ovarian, fallopian tube, and primary peritoneal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Peritoneal Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Doxil (liposomal doxorubicin)

Snippet

Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | Conditions: Ovarian Neoplasms, Fallopian Tube Neoplasms | Phase 2 | Status: COMPLETED | Results posted: 2013-07-12